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Abstract
Mutations in the ABCD1 gene cause the clinical spectrum of the neurometabolic disorder X-
linked adrenoleukodystrophy/adrenomyeloneuropathy (X-ALD/AMN). Currently, the most
efficient therapeutic opportunity for patients with the cerebral form of X-ALD is hematopoietic
stem cell transplantation and possibly gene therapy of autologous hematopoietic stem cells. Both
treatments, however, are only accessible to a subset of X-ALD patients, mainly because of the
lack of markers that can predict the onset of cerebral demyelination. Moreover, for female or male
X-ALD patients with AMN, currently only unsatisfying therapeutic opportunities are available.
Thus, this review focuses on current and urgently needed future pharmacological therapies. The
treatment of adrenal and gonadal insufficiency is well established, whereas applications of
immunomodulatory and immunosuppressive drugs have failed to prevent progression of cerebral
neuroinflammation. The use of Lorenzo's oil and the inefficacy of lovastatin to normalize very-
long-chain fatty acids in clinical trials as well as currently experimental and therefore possible
future therapeutic strategies are reviewed. The latter include pharmacological gene therapy
mediated by targeted upregulation of ABCD2, the closest homolog of ABCD1, antioxidative drug
treatment, small molecule histone deacetylase inhibitors such as butyrates and valproic acid, and
other neuroprotective attempts.
Keywords
4-phenylbutyrate; ABCD1; ABCD2; antioxidant; histone deacetylase inhibitor; Lorenzo's oil;
lovastatin; therapy; valproic acid; X-ALD
Journal Compilation © 2010 International Society of Neuropathology
Corresponding author: Johannes Berger, PhD, Center for Brain Research, Medical University Vienna, Spitalgasse 4, A-1090
Vienna, Austria (johannes.berger@meduniwien.ac.at).
Europe PMC Funders Group
Author Manuscript
Brain Pathol. Author manuscript; available in PMC 2010 November 02.
Published in final edited form as:














X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal neurodegenerative disorder with
a very broad clinical spectrum ranging from the most severe childhood cerebral form to late-
onset adrenomyeloneuropathy (AMN) (8, 70). The fundamental X-ALD symptoms that
presumably all male patients would develop, provided they survive long enough, are those
of a slowly progressive paraparesis, caused by a distal axonopathy that affects most severely
the dorsal columns and the corticospinal tracts in the spinal cord, and represent the major
neurological deficit in AMN (80). The mean age of onset of AMN is 28 ± 9 years but initial
clinical presentation varies from late adolescence to the fifth decade, and occasionally
occurs even later. Female patients (heterozygous carriers, as ABCD1 is located on the X-
chromosome) experience a similar myelopathy, but milder and of later onset. About 65% of
all male X-ALD patients will develop a rapidly progressive, inflammatory, demyelinating
cerebral form (cALD) of X-ALD either in childhood or adulthood. The occurrence of
cerebral demyelination in heterozygous women is exceptional. There are two common
periods for the onset of cerebral inflammatory ALD: the most frequent one between 4 and
12 years of age, with a peak around 7–8 years; and a less frequent one between 20 and 45
years of age, with a peak around 30 years. For untreated patients with childhood cerebral X-
ALD, the 5-year survival rate (from the time of onset of first symptoms) was 59% with
considerable variation in individual survival times (59). In some cases the demyelinating
process can spontaneously stop without further progression (“arrested” cerebral variant)
when it is not associated with disruption of blood-brain barrier at brain magnetic resonance
imaging (MRI). Primary adrenocortical insufficiency is present in approximately 80% of
males with cerebral involvement and approximately 50% of men with AMN, but in only 1%
of women who are heterozygous for X-ALD (59).
The primary cause of the entire clinical spectrum is an inherited mutation (or in only 5% a
de novo mutation) in the ABCD1 gene encoding the peroxisomal protein ATP-binding
cassette (ABC)-transporter D1, in the past referred to as the adrenoleukodystrophy protein
(ALDP). The same mutation can give rise to all different clinical variations even within the
same nuclear family (6). Genetic and environmental factors are suggested to modulate the
clinical outcome of the disease. If X-ALD is suspected in a male patient, or in the term of a
newborn screening, the investigation of very-long-chain fatty acids (VLCFAs) will lead to a
clear diagnosis; the clinical manifestation, however, cannot be predicted. Thus, it is critically
important to monitor brain MRI every 6 months in presymptomatic male patients between 3
and 12 years of age and yearly after that up to 45 years. The inability to predict a future
clinical course represents a major problem concerning the choice of appropriate therapy as
well as the evaluation of the efficacy of clinical trials for novel medication in X-ALD. The
problem is boosted by the fact that X-ALD is a rare disease with an incidence (hemizygous
males plus heterozygous females) of 1 in 16:800 worldwide (9) and, thus, all clinical trials in
X-ALD have been conducted with very low numbers of patients.
Although the entire clinical spectrum of the disease is initiated by mutations in the ABCD1
gene, the pathomechanisms for demyelination, the inflammatory process, the axonal
degeneration and the adrenal insufficiency clearly differ, and thus different therapeutic
strategies must be considered for individual symptoms. Hematopoietic stem cell therapy
(HSCT), for example, is clearly beneficial against the cerebral form of X-ALD, when
performed in a relatively early phase of inflammatory progression, but it is still not known
whether it would be beneficial against AMN symptoms. In this review, we did not include
allogenic HSCT (78) or autologous HSC gene therapy (14), as these approaches are
reviewed in a separate chapter of this mini-symposium (15); here we will focus on different
pharmacological interventions for the various forms of X-ALD and on future strategies and
perspectives for therapies in X-ALD.
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TREATMENT OF ADRENAL AND GONADAL INSUFFICIENCY
Approximately 70% of male X-ALD patients develop primary adrenocortical insufficiency,
often before the onset of neurological symptoms. Thus, all male patients should be
monitored for adrenal insufficiency with plasma adrenocorticotropic hormone (ACTH)
levels and if the results are ambiguous, with the ACTH stimulation test (72). Isolated
measurements of plasma cortisol levels are insufficient and may lead to the false conclusion
(70). The 8:00 am plasma cortisol level may be normal even when it is unresponsive to
ACTH stimulation and the ACTH level is more than 1000 picogram/ml (normal <70). In
affected patients, adrenal hormone replacement therapy is mandatory and effective.
Glucocorticoid dose requirements are generally the same as those used for other forms of
primary adrenal insufficiency. Not all patients require mineralocorticoid replacement.
Hormone replacement therapy does not influence the development or progression of
neurological symptoms (69).
Males with clinical manifestation of hypogonadism that are associated with a low serum
testosterone concentration should receive androgens. Impotence, in most instances, is caused
by spinal cord involvement or neuropathy, rather than testosterone deficiency (70).
Interestingly, many endocrine cell populations express relatively high levels of ABCD1
protein, especially those that also produce proopiomelanocortin (POMC), the precursor of
ACTH and several other peptide hormones (44). Moreover, the POMC-derived peptides β-
lipotropin und β-endorphin colocalize with peroxisomes in cells that express ABCD1, but
the peroxisomal localization of these peptide hormones was not affected in tissues from X-
ALD patients (Höftberger et al unpub. obs.). Whether the cellular changes that are caused by
ABCD1-deficiency in X-ALD patients influence synthesis rate, processing or secretion of
POMC-derived peptides, remains to be investigated, and may add a further level of
complexity to the endocrinological aspects of X-ALD pathology, which are usually
attributed to local toxicity of accumulated VLCFAs.
LORENZO'S OIL
Although the levels of VLCFAs in serum or cultured fibroblasts of X-ALD patients appear
indistinguishable among patients affected by different disease severity, the in vivo amount
of VLCFAs in particular cell types or lipid classes, such as gangliosides and other complex
lipids, might play a crucial role in the mechanism underlying AMN and cerebral
inflammatory ALD. In good agreement with this hypothesis, Asheuer et al (3) reported
higher C26:0 levels in normal appearing white matter of patients with the childhood cerebral
phenotype than in those with AMN. There is also growing evidence that oxidative stress
contributes to the pathogenesis of X-ALD and that excess of VLCFAs plays a role in this
process (29, 41, 81). Thus, there is a good rationale for therapies aiming at lowering
VLCFAs in the central nervous system (CNS). The reduction of VLCFAs might be
beneficial for all different clinical manifestations of X-ALD; the targeted molecular
mechanism, however, might differ, for example, autoantigenic activity via CD1-mediated
presentation of gangliosides and other lipids containing VLCFAs in the inflammatory
process, vs. VLCFA as a primary cause of oxidative stress in the susceptible long cortico-
spinal tracts in AMN.
Oral administration of “Lorenzo's oil,” a 4:1 mixture of glyceryl trioleate and glyceryl
trierucate, combined with moderate reduction of fat in the diet, normalizes or significantly
lowers the levels of VLCFA in plasma within 4 weeks (88), but its clinical efficacy and the
clinical indications for its use have been controversial for more than 15 years. Based on
several open clinical trials including asymptomatic and symptomatic patients, it was
concluded that there is no clinically relevant benefit from dietary treatment with Lorenzo's
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oil (4, 103). The treatment could neither ameliorate nor arrest the rapid progression of
neurological symptoms in cerebral variants of X-ALD, and asymptomatic patients have
developed the severe, rapidly progressive, inflammatory demyelination (eg, (4, 103)).
However, a study involving 89 asymptomatic X-ALD patients with normal brain MRI and a
mean age of 4.7 years at enrollment and a follow-up period of 6.9 ± 2.8 years suggests that
substantial and consistent reduction of plasma C26:0 levels led to a twofold or greater
reduction in the risk of developing the childhood cerebral form of X-ALD (71). There was a
moderate reduction of platelet count in approximately 30% of patients, but this could be
managed by adjustment of Lorenzo's oil dosage. The dietary therapy requires a careful
supervision by a multidisciplinary team including a nutritionist to ensure that the VLCFA
levels are lowered and that nutritional balance is maintained.
Köhler and Sokolowski conducted an open study on 45 men with pure AMN (53). The
patients were followed for an average period of 6.3 years (range 2–12.8 years), during which
22 patients (48%) remained stable. In 84% of patients with disease progression, the
progression during therapy was significantly slower than it had been during the pretreatment
period. Unfortunately, it is not possible to draw definitive conclusions because of the open
study design, the relatively small number of treated patients, and marked variability of AMN
progression on an individual basis. Furthermore, the findings are in contradiction to earlier
studies (4, 103). Lorenzo's oil teaches a lesson about how raising early hope in patients
creates ethical issues that prevent double-blind studies, which in combination with the lack
of knowledge concerning the molecular mechanism of a disease and the relatively low
patient numbers, have led to a situation where the efficacy of a therapy is still unknown even
after 20 years of use in probably more than 500 patients.
FAILURE OF IMMUNOMODULATORS AND IMMUNOSUPPRESIVE DRUGS
As the rapid progression of X-ALD is associated with brain inflammation, reduction of this
response could be of therapeutic benefit. Unfortunately, so far all studies attempting
immunosuppressive or immunomodulating therapies have not been successful. Severe
immunosuppression with cyclophosphamide failed to prevent neurological progression in a
patient with adrenoleukodystrophy (98) and in four out of five patients in a later
investigation (75). Interferon (IFN)-β can suppress the synthesis of IFN-γ and tumor
necrosis factor (TNF)-α, both of which have been potentially implicated in the pathogenesis
of X-ALD. Eight patients with cerebral X-ALD were treated with Lorenzo's oil (glycerol-
trioleate/glyceroltrierucate) in combination with subcutaneous injections of IFN-β1a, but the
treatment did not affect the clinical progression (52).
Intravenous immunoglobulins (IVIGs) were reported to be helpful in one patient with
adolescent cerebral ALD (65) but without clear benefit in 11 out of 12 patients in a second
investigation (67) and without clinical benefit in a third study involving 12 childhood
cerebral X-ALD patients under Lorenzo's oil, of which six received IVIGs and six did not
(12). An anecdotal plasma exchange did not alter the course of the disease (74). However,
when combined with dextran sulphate absorption of VLCFA it improved clinical
performance and well-being in one patient (5). In addition, several open trials, each
performed in 20–25 children with cerebral X-ALD, applying IVIG therapy or
immunosuppressive drugs, like cyclosporine or mitoxantrone, showed no effect (P.
Aubourg, unpub. obs.). Based on initial, promising results in multiple sclerosis (MS),
Tysabri (NatalizumAb; monoclonal antibody therapy directed against integrin alpha-4
adhesion molecules on activated white blood cells, preventing their entry into the CNS) was
tried in two X-ALD patients that were too advanced for HSCT, but without success (Jutta
Gärtner and Robert Steinfeld, pers. comm.).
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Despite some resemblance between the inflammatory lesion in cerebral X-ALD and some
subtypes of MS, the failure of all these immunomodulatory/suppressive therapies likely
reflect that the physiopathogenesis of neuro-inflammation in X-ALD is in fact completely
different, and not just that cALD progresses more rapidly than the typical relapsing-
remitting forms of MS. The mononuclear phagocytic cell response in cerebral X-ALD
shows a distinct pattern, suggesting that the inflammatory reaction trails behind rather than
leads the tissue injury (91). Microglial apoptosis in perilesional white matter appears to be
an early event in lesion evolution and thus may represent a therapeutic target in X-ALD
patients with cerebral demyelination (21).
INEFFICACY OF LOVASTATIN TO NORMALIZE VLCFA
Modulation of cellular cholesterol by either cholesterol depletion (107) or treatment with the
cholesterol-lowering drug lovastatin (95) normalizes VLCFA accumulation in primary
cultured human X-ALD fibroblasts. On the other hand, high cholesterol levels could
increase levels of VLCFA in cultured human fibroblasts from X-ALD patients or controls
(108). Abcd1-deficient X-ALD mice (26) show an increased plasma cholesterol level,
comparable with the level observed in high cholesterol-fed wild-type controls. In contrast to
the wild-type mice, the plasma cholesterol level could not be further increased by high
dietary cholesterol in the Abcd1-deficient mice (108). However, neither treatment with
lovastatin (112), nor simvastatin (13), nor lovastatin combined with colestipol (a cholesterol-
lowering bile acid sequestrant) (108) normalized the levels of VLCFA in tissues of the X-
ALD mice. Only in one study, where isolated brain white matter was analyzed (in contrast to
whole brain in the other studies) after 3 weeks of lovastatin treatment, was a reduction of
VLCFA accumulation reported in the X-ALD mouse model (48).
In two clinical trials, involving 7 and 12 X-ALD patients with different phenotypes that
were treated with 20–40 mg lovastatin per day for up to 12 months, reduced levels of
VLCFA in plasma were reported (77, 95). A different study of six children with X-ALD,
treated for 3 months with 0.2–1 mg simvastatin/kg body weight/day, failed to observe a
reduction in plasma VLCFA (105). A recently reported randomized, double-blind, placebo-
controlled, crossover trial, including 14 AMN patients and comparing lovastatin at a dose of
40 mg once daily with placebo (22), did observe a slight decrease of VLCFA levels in
plasma after 8 weeks. But even after reduction, C26:0 remained above the control level and
was no longer significant at 22 weeks. The decrease in VLCFA was considered to be a non-
specific result of the decrease in the level of LDL cholesterol. C26:0 levels in peripheral-
blood lymphocytes, erythrocytes and in the LDL lipoprotein fraction were not altered after
the treatment. It was concluded that lovastatin should not be prescribed as a therapy to lower
levels of VLCFA in patients with X-ALD (22). These studies did not report any clinical
benefit for the neurological symptoms.
PHARMACOLOGICAL INDUCTION OF THE REDUNDANT GENE ABCD2 AS
POSSIBLE THERAPEUTIC APPROACH
Mutations in the ABCD1 gene encoding the peroxisomal ABC-transporter ABCD1 is the
initial cause of X-ALD regardless of clinical variant. ABCD1 is a half ABC-transporter,
forming predominantly homodimers (36, 42), but may also form heterodimers with other
peroxisomal ABC-transporters (58, 96, 100). There are at least three peroxisomal ABC-
transporters. Whereas the peroxisomal localization of ABCD1, ABCD2 (ALDRP,
adrenoleukodystrophy-related protein) and ABCD3 (PMP70, peroxisomal membrane
protein 70 kD) is undisputed, a recent study doubted the peroxisomal localization of ABCD4
(P70R/PMP69), the fourth member of the ABCD transporter family (45). ABCD2, the
closest homolog of ALDP shares 66% amino acid identity (43) and when overexpressed in
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cultured human fibroblast cell lines from X-ALD patients, it can normalize the peroxisomal
β-oxidation and prevent accumulation of VLCFAs (25, 76). Moreover, when murine
ABCD2 protein is ubiquitously overexpressed from a transgene under the control of the β-
actin promoter in Abcd1-deficient mice, it can normalize VLCFA levels in the target tissues
(brain, spinal cord and adrenals) and rescue late-onset motor coordination defects (85).
Moreover, partially overlapping functions of these transporters regarding accumulation of
VLCFA and β-oxidation of VLCFA ex vivo have been reported (30). Also early signs of
oxidative stress in spinal cord of the mouse model were counteracted by the transgene (31).
As ABCD2 protein can substitute for the lack of ABCD1 in vitro and in vivo, it is strongly
suggested that these two ABC-transporters have similar and overlapping substrate
specificities. The different, rather complementary expression patterns of murine and human
ABCD1 and ABCD2 (7, 55, 101) and the level of ABCD2 expression in critical cell types
could be the reason why ABCD2 cannot compensate for the loss of ABCD1 in X-ALD
patients. Furthermore, the two genes are regulated in opposite directions under some
potentially disease-relevant conditions, for example, in response to cholesterol-loading of
human peripheral blood monocytes (51). We have also demonstrated that ABCD2 is not
mutated in X-ALD patients and that the X-ALD phenotype is independent of the ABCD2
genotype (60).
Thus, pharmacological induction of ABCD2 should be able to compensate for the lack of
functional ABCD1 in X-ALD patients, if the induction is sufficiently strong and targets
disease relevant cell types. Two main questions considering the induction of ABCD2 as
therapeutic approach in X-ALD are: (i) which cell types have to be targeted for the
pharmacological induction of ABCD2?; and (ii) is it necessary that a compound passes the
blood–brain barrier? HSCT can arrest the demyelinating process when performed at an early
stage of inflammation. None of the successfully treated patients developed newly emerging
neuroinflammation and cerebral demyelination at later time points, after more than 20 years
of follow-up (78). Probably perivascular macrophages and resting microglia are the main
cell populations that continually renew from bone marrow hematopoietic stem cells and/or
myeloid progenitors in the brain. The success of the hematopoietic stem cell gene therapy
(14) suggests that only a limited number of microglia cells needs in fact to be corrected to
arrest the demyelinating process. At 24–30 months after ex vivo correction of the patient's
own CD34+ cells using a lentiviral-based ABCD1 vector and re-infusion into the patient,
Cartier and coworkers (14) detected ALDP in 9%–14% of granulocytes, monocytes, and T
and B lymphocytes. Although one cannot completely exclude a selective advantage of
corrected microglia, this percentage of correction was sufficient to arrest the inflammatory
demyelinating process in two patients. The clinical benefit could also be caused by the
overexpression of ALDP in these cells. Thus, in our view, induction of ABCD2 in the
macrophage/microglia population represents an attractive therapeutic target concerning the
inflammatory phenotype. In addition, it is possible that the compound does not have to pass
the blood–brain barrier in order to be effective. Possibly, cells initially treated in the
periphery can migrate into the brain or secrete some peroxisome-derived, trans-acting
metabolite with beneficial effects in the CNS. For example, in a cre-lox mouse model the
lack of peroxisomes exclusively in the liver (albumin/α-fetoprotein-cre×Pex5-loxP) leads to
abnormalities in brain development (54).
The concept of targeted therapeutic induction of ABCD2 has initiated intense investigations
aiming to modulate the rodent and human ABCD2 gene expression. Early studies had
indicated that 4-phenylbutyrate (47), discussed in the following in the context of histone
deacetylase (HDAC) inhibitors, and fibrates activate ABCD2. Fenofibrate and other related
compounds with peroxisome proliferating activity also strongly upregulated ABCD2 mRNA
levels in liver and intestine (but not in brain) of rats and mice (1, 2, 7, 27). Also highly
potent, specific peroxisome-proliferator activated receptor α (PPARα) agonists (GW7647,
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GW6867 and tetradecylthioacetic acid) induced Abcd2 in mouse liver and adrenals (86).
This response to fibrates was abolished in PPARα knockout mice. But no functional
response element (PPRE) could be identified in the Abcd2 gene in any of these studies,
leading to the hypothesis that the PPARα agonist-mediated effect is indirect (7, 27, 86).
Because a PPARα-dependent increase in the sterol regulatory element-binding protein
(SREBP) 2 mRNA level could be demonstrated in the liver of fenofibrate treatment mice,
we hypothesized that the PPARα agonist-mediated induction of Abcd2 expression is
indirect by SREBP2 (86).
Detailed promoter analyses demonstrated that ABCD2 expression is induced upon sterol-
depletion in cultured human and murine monocytes as well as in human primary fibroblasts.
Reporter gene studies, site-directed mutagenesis and gel shift assays have identified a
functional sterol regulatory element (SRE) as a key regulatory element in the promoter of
ABCD2 (107, 109). This finding provides a link between ABCD2 expression and possible
positive effects of cholesterol-lowering compounds such as lovastatin, which leads to
maturation and nuclear translocation of the transcription factor SREBP and subsequently to
activation of ABCD2 expression and reduced VLCFA accumulation. As described earlier,
apparently lovastatin (or related statins) alone is not sufficient to normalize VLCFAs in
human X-ALD patients or in the murine X-ALD model. This might be related to the
complex context of the SRE motif in the ABCD2 promoter.
The SRE motif overlaps with a direct repeat (DR4) element, which can bind several nuclear
receptors that form heterodimers with retinoid X receptor (RXR), such as liver X receptor
(LXR)α (109) or thyroid hormone receptor (TR) α and β (28, 110). The RXR agonist cis-
retinoic acid induces transcription of endogenous ABCD2 in human NT2 cells (101) and of
the human and rodent ABCD2 promoter in transfected cells (83); however, in these studies a
direct interaction with a specific promoter element was not demonstrated. Whereas RXR
agonists can further induce SREBP-mediated activation of the promoter in reporter gene
assays (J. Berger, unpub. obs.), LXRα agonists counteract the SREBP-induced response of
ABCD2 (109). Thus, in a scenario where oxidized sterols, the natural ligands for LXR,
would downregulate ABCD2 expression, an LXRα selective antagonist could represent a
possible therapeutic intervention. Both TRα and TRβ bind the DR4 motif in the ABCD2
promoter, but whereas thyroid hormone-liganded TRα activates the gene, a repressive
response seen by unliganded TRβ appears to be relieved by hormone-binding, especially in
the context of SREBP-activated ABCD2 expression (110). Thyromimetics (GC-1 and CGS
23425) specific for TRβ1 were recently shown to induce ABCD2 in human HepG2 cells as
well as in primary X-ALD fibroblasts (33). Thus, understanding the relationship between the
transcriptional activation mediated by SREBP and a complex network of DR 4-binding
transcription factors, including TRα, TRβ, LXRα and RXRα, will help to select and test
more specific agonists or antagonists for a safe yet effective modulation of ABCD2
expression in X-ALD patients.
For preclinical proof-of-concept, promising compounds can be tested in cultured
macrophage/microglial cell lines and primary monocytes/macrophages, in ABCD1-deficient
cells in culture, and in vivo in the X-ALD mouse model. Of some concern for the
pharmacological induction of ABCD2 in X-ALD patients, was a possible dominant negative
effect of certain ABCD1 mutations, resulting in stable inactive protein when forming
heterodimers with the induced ABCD2 protein (102). However, accumulating evidence
indicate that ABCD1 and ABCD2 predominantly form homodimers (36, 42) making this
argument less important for pharmacological gene therapy, but it may still indicate some
caution for the gene therapy of autologous hematopoietic stem cells using viral vectors in X-
ALD.
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HDAC INHIBITORS AS POTENTIAL THERAPEUTIC AGENT
The net effect of most transcription factors that bind specific gene regulatory motifs and act
as activators or repressors of gene expression, is the recruitment of histone acetyl
transferases (HAT) or HDACs, respectively, usually via additional layers of protein–protein
interactions with coactivators or corepressors. HDACs remove the acetyl groups from the
lysine residues of core histones leading to locally condensed, transcriptionally silenced
chromatin. Blocking of this activity results in hyperacetylation and thus increased
transcription rates at the affected promoter. This family of enzymes is now also
appropriately being referred to as lysine deacetylases (KDACs) to include their function on
non-histone, lysine-containing targets (16), which among others include transcription factors
(e.g. NFκB, p53, Sp1) and their co-regulators.
In higher eukaryotes, 10 different “classical” HDAC proteins (HDAC1–10) are grouped
either into class I or II (reviewed in (17)) and are all inhibited by tricostatin A. Class I
HDACs are widely expressed and are normally considered constitutively nuclear proteins,
whereas classes II HDACs show more tissue specificity and shuttle between the nucleus and
the cytoplasm (66). Nuclear export of HDAC1 has recently been implicated in pathological
demyelinating conditions and may be essential for the onset of axonal damage, as it was
identified as a critical event for impaired mitochondrial transport in damaged neurons (50).
Small-molecule HDAC inhibitors interfere with class I and II HDAC activity by binding to
the Zn-containing catalytic domain and can achieve significant biological effects in
preclinical models of cancer (66), but also in neurodegenerative diseases like Huntington's,
Parkinson's or Alzheimer's disease (38). The most potent group is hydroxamic acids, such as
tricostatin A and the second generation drug vorinostat (SAHA) that has been used with
success in preclinical and clinical trials. Small organic acids, such as phenylbutyrate and
valproic acid (VPA), have more favorable toxicity profiles but much lower potency, because
of rapid absorption in the gastrointestinal tract after oral administration and to albumin and
other plasma proteins (93). Because of its anticonvulsant effects, VPA is widely used in
treatment of epilepsy.
Application of HDAC inhibitors have been used to target induction of specific genes or
relied on global effects on transcription. Some examples of pharmacological treatment
strategies for genetic diseases include: the induction of fetal hemoglobin in beta-globin
disorders (18), the upregulation of utrophin in dystrophin-deficient muscle cells in
Duchenne's muscular dystrophy (49), the stimulation of survival of motorneuron 2 (SMN2)
transcription and the correction of SMN2 mRNA splicing by HDAC inhibitors as a potential
therapy for spinal muscular atrophy (11, 37). HDAC inhibitors have also been identified as
candidate drugs for treatment of several neurodegenerative disorders, including amyotrophic
lateral sclerosis, Huntington's, Parkinson's and Kennedy's disease, where perturbation of
histone acetylation homeostasis and transcriptional dysregulation of disease-modifying
genes clearly play a role in the pathomechanism, reviewed in (38, 46). Several recent studies
also indicate that HDAC inhibitors can have an immunomodulatory effect on regulatory T
cells, reviewed in (106), and on glial inflammatory responses (23).
4-Phenylbutyrate (4-PBA)
Initial studies with cultured cells showed that small organic acids, such as phenylacetate
(94), or its prodrug 4-PBA (47) could reduce the level of VLCFA in X-ALD fibroblasts,
which was attributed to increased peroxisomal β-oxidation rates. Kemp and coworkers also
showed increased levels of ABCD2 mRNA and peroxisome proliferation in cultured human
and murine primary fibroblasts (both wild-type and X-ALD cells) after 4-PBA treatment. In
Abcd1-deficient, but not wild-type, mouse fibroblasts, also the level of ALDR protein
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increased. Most importantly, in a preclinical trial, a substantial reduction of VLCFA (C26:0
and C24:0) was achieved in the brain and adrenal glands of Abcd1-deficient mice after 4 and
6 weeks of dietary 4-PBA treatment (47). The article did not show any results on gene
expression or peroxisome numbers in the treated mice. However, it was later reported that
long-term continuous administration of 4-PBA in Abcd1-deficient mice leads to a reduced
drug response (tachyphylaxis) and a return to pretreatment levels of VLCFA (63).
The effect of 4-PBA on peroxisome proliferation was considered atypical, because it did not
involve the induction PPARα and acyl-CoA oxidase (Acox) gene expression that typically
accompany peroxisome proliferation. Instead, peroxisome biogenesis factor 11 (PEX11)α
was selectively induced together with ABCD2 (47). It was subsequently shown in
Pex11α(−/−) mice that hepatic peroxisome proliferation in response to 4-PBA requires
PEX11α but is independent of PPARα (57), and in Pparα(−/−) cells, the activation of
Abcd2 by 4-PBA was unaffected (35). Further studies applying 4-PBA considered the
inhibition of HDAC activity, as the mode of induction of ABCD2 and PEX11α expression
and peroxisome proliferation (35, 63, 64). Direct comparisons with the highly potent HDAC
inhibitor tricostatin A, showed increased mitochondrial and peroxisomal β-oxidation after
application of either drug to cultured fibroblasts, but only 4-PBA induced expression of
ABCD2 (63, 64). In human X-ALD fibroblasts, the effect of 4-PBA was described to first
increase mitochondrial β-oxidation of long-chain fatty acids, followed by increased
peroxisomal VLCFA β-oxidation, which preceded the upregulation of ABCD2 mRNA
levels. After 8 weeks of oral 4-PBA treatment of Abcd1-deficient mice, VLCFA levels in
post-nuclear supernatants of liver tissue were partially reduced by both 4-PBA and
tricostatin A, without increased rates of peroxisomal or mitochondrial β-oxidation (64). The
effect on VLCFA levels in brain or adrenal glands was not addressed here; but
ultrastructural studies of the adrenal glands in 1-year-old Abcd1-deficient mice, which had
received 4-PBA for 1 month, revealed less structural abnormalities of mitochondria than
untreated mice (64).
In another study (35), where 4-PBA was applied to rats orally, long-term (6–9 weeks) or
short-term (by i.p. injections for several days), to study acute effects on gene expression,
showed peroxisome proliferation and increased amounts of ABCD2 and ACOX mRNA in
liver, but unaltered levels in brain (and several peripheral tissues including kidney, spleen
and testes). In oligodendroglial and astrocytic cell lines and primary cultures, Abcd2 but not
Acox was induced by 4-PBA and butyrate.
Gondcaille and coworkers also identified key elements for the 4-PBA-dependent induction
of the rat Abcd2 promoter using reporter assays in transfected COS-7 cells and DNA
binding assays with hepatic nuclear extracts. The authors showed that these GC1 box and
CCAAT motifs in the immediate upstream region of the Abcd2 gene bind their cognate
transcription factors, Sp1/Sp3 and NF-Y, respectively, and that HDAC1 is recruited to the
GC1 box. For full induction, both elements appears to be required, suggesting a synergistic
effect, possibly involving recruitment of HAT activity for gene activation (35). Studies of
these interactions in vivo will be required to further substantiate this interesting observation.
It also remains to resolve whether such recruitment and modulation of HAT activity to
antagonize HDACs represents a direct effect on histones and chromatin remodelling or
involves acetylation of lysine residues of other protein targets, for example, leading to
modified activity Sp1/Sp3 (99).
Clinical applications of 4-PBA and arginine butyrate in human X-ALD patients
Based on clinical applications of 4-PBA for induction of the fetal globin gene in human
beta-globin disorders and the initial, promising effects of 4-PBA in the mouse model of X-
ALD (47), 4-PBA was given orally to seven adult AMN patients in a preliminary clinical
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study (Raymond, Watkins, Moser, unpub. obs., reviewed in (70)) for two periods of 6
weeks, interrupted by 2 weeks off medication. Although magnet resonance studies of the
brain, done in one patient 30 min after administration of 4-PBA, had demonstrated the drug
in brain white matter and cerebrospinal fluid, no substantial alterations of VLCFA β-
oxidation in white blood cells or of VLCFA levels in plasma, red cells or white blood cells
were noted; only C22:0 and C24:0 in platelets were reduced. Analysis of ABCD2 mRNA
levels in white blood cells from three of the patients showed no significant change.
Possible complicating factors that contributed to the poor response were suggested to be the
short half-life of 4-PBA, which in vivo is quickly metabolized in the liver, and
tachyphylaxis. These effects might be counteracted by applying a different (interval)
treatment regime. Other pharmacological agents that are functionally and/or structurally
related to 4-PBA, but with more longlasting pharmacokinetic properties, were suggested to
be tested for their ability to correct the accumulation of VLCFA in X-ALD fibroblasts (63).
To circumvent the problems associated with the large amount of medication needed with
oral 4-PBA, an intermittent pulsed regime of intravenous arginine butyrate was developed
for treatment of hemoglobinopathies. A case report describes an open trial of intravenous
infusion of arginine butyrate during 4 months, with intermittent days off medication, in one
patient with childhood cerebral X-ALD (62). The treatment was well tolerated and quickly
led to a substantial decrease in plasma VLCFA, showing that this class of compounds can
reduce VLCFA levels also in human patients. However, in this patient, the neurological
deterioration progressed during treatment, possibly related to the fact that the inflammatory
process in the CNS was already underway at the start of the trial. Further clinical studies
would be needed to determine effective dosage and interval, and whether neurological
degeneration can be prevented with an earlier onset of treatment.
Valproic acid (VPA)
The short-chain fatty acid VPA is a class I-selective HDAC inhibitor with anticonvulsant
effects and thus widespread clinical use in treatment of epilepsy. It is well tolerated and
passes the blood–brain barrier. VPA provides neuroprotective effects in vitro and clinical
improvement in spinal muscular atrophy patients (38). Exposure to VPA induces extensive
changes in the transcriptome. More than a thousand genes were identified by microarray
analysis as being VPA-responsive in the liver of mice after subchronic oral treatment (56);
interestingly, among many genes involved in cholesterol and fatty acid metabolism,
including Abcd2, Pex11a, Acox, and several elongases (Elovls) were noticed. Of interest for
neurodegenerative aspects, also in a study of primary cultures of rat cortical neurons Abcd2
emerged as responsive (strongly upregulated) to VPA (32).
In a recent study, Pujol and coworkers evaluated the neuroprotective potential of VPA in X-
ALD, particularly targeting AMN (31). The authors showed that VPA induces expression of
ABCD2 in human X-ALD fibroblasts via inhibition of HDAC, and that oxidative lesions to
proteins are significantly reduced by VPA. Thus, it was expected that VPA should reduce
VLCFA levels as well. However, whereas C26:0 was not significantly altered, C26:1 was
partially reduced in human X-ALD fibroblast. In the spinal cord of X-ALD mice,
overexpression of ABCD2 corrects VLCFA levels and the late-onset neurological phenotype
(85) and in mice with targeted deletions of both Abcd1 and Abcd2, overexpression of
murine ABCD2 protein prevents oxidative damage. Although VPA induced Abcd2
expression in hippocampal slice cultures from rat and mouse (wild-type and Abcd1-
deficient), as well as in human cortical slices, the accumulation of saturated (C26:0) VLCFA
could not be rescued by VPA in Abcd1 or Abcd1/Abcd2 double-deficient slice cultures.
Only mono-unsaturated (C26:1) was partially reduced in the single but not in the double-
knockout preparations. As a possible explanation for the discrepancy between induction of
ABCD2 and the lack of effect on saturated VLCFA levels, it could be demonstrated that the
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mRNA levels of several elongase genes (ELOVL3, ELOVL4 and ELOVL5) are elevated by
VPA in human X-ALD fibroblast (31). As the corresponding enzymes are involved in chain-
length elongation during fatty acid synthesis, their increased expression could generate more
VLCFA and, thus, counteract the increase in degradation recruited by elevated ABCD2.
Clinical trial of VPA in human X-ALD patients
Because VPA is metabolized very quickly in the liver of mice, no preclinical study was
carried out in the mouse model. Instead, as VPA is a well-established and well-tolerated
medication, a small clinical trial was performed in five X-ALD patients (31). VPA
(Depakine) was administered orally (40 mg/kg/day) for 6 months without side effects. The
ABCD2 mRNA levels were slightly increased above baseline in peripheral blood monocytes
after 6 months, but the elevated concentrations of VLCFA (both C26:0 and C26:1ω9) were
not corrected. However, the markers for oxidative damage were completely normalized or
strongly reduced at the end of treatment. These results suggest that VPA induces antioxidant
effects in X-ALD, which could be of significant benefit especially for patients with AMN
(31).
ANTIOXIDANT STRATEGIES
A wealth of human data consistently supports the idea that oxidative stress occurs and is a
constant feature of aging and neurodegenerative disease. Some recent evidence even
suggests that this phenomenon is an early event and may play a role in the pathogenesis of
several neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease or
amyotrophic lateral sclerosis (90, 113).
Evidence of oxidative damage in X-ALD has been reported in post mortem brain samples
from patients with cerebral X-ALD, which show induction of iNOS and nitrotyrosine in
astrocytes and microglia from the affected white matter (34), and also increased
immunoreactivity to markers of lipoxidative damage (81). Additional data collected in the
plasma of X-ALD patients using the thiobarbituric acid test indicate that oxidative stress
might not be restricted to affected white matter in the brain, but might be a more general
process, and could be used as a disease biomarker (104). In the X-ALD mouse model that
mimics mild AMN, time course experiments have provided compelling evidence of
oxidative damage of proteins very early in life, at 3 months of age, long before the
neuropathological and neurological signs of disease occur at 18–20 months (29). Thus,
oxidative damage could be linked to both the initiation and the progression of
neurodegeneration in X-ALD. The origin of this oxidative damage is being intensively
studied. Current evidence points to the excessive production of free radicals caused by the
accumulation of hexacosanoic acid, and to an impaired response of the antioxidant defense
system(s) to oxidative insults (29, 82).
In spite of promising epidemiological data, antioxidant therapies have been applied to
several neurodegenerative conditions with limited success. Pitfalls include: (i) endogenous
levels of antioxidants in the treated patients were not controlled, and this is of importance as
patients might react differently to antioxidants based on baseline levels; (ii) the in vivo
antioxidant effects of the drug and patients compliance were not monitored (39); (iii) the
causality link between oxidative stress and disease was not precisely established; (iv) trials
were performed in patients with extensive pathologies, where preventive actions might have
been too late; (v) the doses used might be wrong—there is some evidence to date that lower
doses and/or mixtures of antioxidants might have more benefits than higher doses of single
agents (10, 89).
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Antioxidants seem in general, better at decreasing oxidative damage in rodent models of
disease, and simultaneously beneficially affecting disease progression, than they do in
humans (40). However, in diseases in which oxidative stress is well established as the
primary cause, these type of approaches might be of interest. A good example is Friedreich
Ataxia, caused by depletion of frataxin, a mitochondrial protein implicated in the iron-sulfur
metabolism and production of mitochondrial reactive oxygen species (ROS). Idebenone
helped in a mouse model and has also improved cardiac hypertrophy in patients at high
doses (79, 92).
Our studies in the last years on X-ALD physiopathogenesis using the mouse models of the
disease have yielded a strong rationale to support preclinical studies focusing on improving
oxidative damage in X-ALD. Moreover, we can use highly sensitive and quantitative
markers of oxidative lesions, which were identified first in the murine model and then
validated in X-ALD patients' lymphoblasts, to faithfully monitor the beneficial effects of
antioxidants (31). These markers have been used to uncover an antioxidant effect of VPA in
X-ALD patients, a drug that might combine HDAC inhibitory properties with antioxidant
effects and, thus, be of benefit for X-ALD patients.
Recently, we have identified a combination of antioxidants that is able to reduce ROS
production in vitro and to normalize oxidative lesions to proteins in vivo in spinal cords of
X-ALD mice (Lopez-Erauskin J, Glia 57, S100, 2009). Work in progress will tell us whether
this correction correlates with an arrest or prevention of neurodegeneration in this mouse
model. A successful result of the preclinical trial with antioxidants would deliver the proof-
of-concept on the contributing vs. causative role of oxidative stress in X-ALD pathogenesis.
Extensive experimental data concerning the intracellular sources of ROS, the organelles and
enzymatic systems involved, and the cell types responsible for the generation and
homeostasis of ROS in the X-ALD murine model are required before a rational strategy with
reasonable odds of success might be proposed to patients. Effectiveness of this therapeutic
strategy will likely apply only to AMN patients, and at best for patients at very early stage of
demyelination.
ADDITIONAL GENERAL NEUROPROTECTIVE EFFORTS
Insulin-like growth factor-1 (IGF-1) and neurotrophin-3 (NT-3)
Addressing features of axonopathy and related destabilization of myelin in the CNS in X-
ALD, a recent study in mice was carried to evaluate the potential therapeutic benefit of the
growth factors IGF-1 and NT-3 (61). Recombinant adeno-associated viral vector (serotype
6), engineered to produce either IGF-1, NT-3 or enhanced green fluorescent protein (EGFP,
as a negative control), were administered into the cerebrospinal fluid of Abcd1/Abcd2
double-deficient mice, a model for X-ALD (85), for a continuous source of these growth
factors. Mice with targeted inactivation of both Abcd1 and Abcd2 develop late-onset AMN-
like myelopathy and axonal degeneration in the spinal cord, months before axonopathy and
motor behavior-deficits are detected in Abcd1 single mutant mice (24, 84, 85) and were
selected for this trial in order to allow evaluation of long-term therapeutic efficacy on
disease progression. After injection of the vectors at 17 months of age, the expected
transduction of ependymal and leptomeningeal cells was demonstrated and 20 weeks after
treatment, IGF-1 and NT-3 were still detectable by ELISA in the CSF (61). Motor
performance was tested every second week over a 4-month-period; before injection, the
motor performance of the double-mutant mice had already started to deteriorate when
compared with the wild-type controls, and in the EGFP-treated “X-ALD” mice it continually
worsened, whereas the motor behavior of mice treated with either IGF-1 or NT-3 vector
improved over time to the levels of untreated wild-type controls. Twenty weeks after
treatment, the extent of myelination in the spinal cord, as revealed by morphometric analysis
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of immunohistochemical staining for proteolipid protein (PLP), was indistinguishable in
untreated wild-type and “X-ALD” mice treated with neurotrophic factors, whereas the
EGFP-treated control mice showed severe loss of myelin (61).
Thus, this long-lasting, gene therapy-based delivery of trophic support for oligodendrocytes
showed a protective effect against the demyelination process and appeared to arrest
progression of the disease. Although in this study sufficiently large numbers of mice/group
were analyzed, no untreated mutant mice or mock (ie, EGFP)-treated wild-type mice were
used as controls. Therefore, neither any effects from the procedure or the vector (expressing
EGFP) alone nor the range of possible improvement can be assessed. Also, the limited
histopathological analysis does not address therapeutic effects on other neurodegenerative
features, like axonopathy or microglia activation. Nevertheless, this approach delivers hope
for therapeutic intervention aiming to limit primary loss of oligodendrocytes and myelin.
Modified cobratoxin
As Immunokine had been tried in several patients with MS and AMN under non-placebo
controlled conditions with initial encouraging results, a study was designed to elucidate
whether Immunokine, can improve clinical symptoms in eight AMN patients (mean age
46.7 ± 15 years) with spastic paraparesis that caused walking difficulties. Immunokine is a
peptide derived from Thailand cobra venom. It is a detoxified α-toxin, binding to nicotinic
acetylcholine receptors at neuromuscular junctions and in neuronal synapses of the brain.
Modified cobratoxin was given orally in a double-blind, randomized, crossover (after 3
months) study without significant clinical benefit in the AMN patients (73).
IMPROVED METHODOLOGY FOR EVALUATION OF DISEASE
PROGRESSION AND THERAPEUTIC EFFICACY
Considerable efforts have been invested in the last years to develop methods and techniques
to permit a more rapid evaluation of therapeutic interventions. Eichler et al (19) have shown
that MR spectroscopy might be predictive of clinical outcome and may be further
substantiated by using additional new imaging approaches, such as diffusion tensor imaging
and magnetization transfer (MT) MRI. Hopefully the combination of these imaging
techniques, combined with clinical data, will facilitate greatly the assessment of therapeutic
interventions in the cerebral forms of X-ALD in children and in adults (20). Quantitative
tests of sensory and motor functions (68), together with MT MRI of the cervical spinal cord
(97), should make a more rapid evaluation of the efficacy of potential therapeutics possible
also for AMN patients. However, the predictive value of even more sophisticated MRI
techniques is limited and there is still an urgent need for a biological markers that can
predict disease evolution. The identification of modifier genes will hopefully be of
additional predictive value for an early estimation of future clinical manifestation in X-ALD.
Thus, on the one hand, the increasing knowledge of the molecular mechanisms underlying
the different clinical manifestations of X-ALD has lead to possible novel therapeutic
approaches and, on the other hand, has established systems that should allow efficient and
rapid evaluation of the efficacy of upcoming novel therapeutic approaches.
HEAD TRAUMA AS RISK FACTOR FOR CONVERSION TO CEREBRAL X-
ALD
A report by Raymond and colleagues on five patients (87), as well as other reports
(summarized in (87)), and own observations in two cases (P. Aubourg, unpub. obs.) disclose
head trauma as one environmental risk factor able to trigger the rapidly progressive
inflammatory demyelination in AMN patients. The initiation of demyelination in some of
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these cases appears at the same area as the original contusion (87, 111, and P. Aubourg,
unpub. obs.). Thus, head trauma represents one of several potential environmental factors
that can trigger the cerebral phenotype in those X-ALD patients, who are genetically at risk
for cALD. Other environmental factors could possibly be viral infections. Thus, in addition
to the obligate inherited ABCD1 mutation and the accumulation of pathogenic lipids,
modifier genes will likely add to a predisposition for cerebral inflammatory phenotype that
is finally triggered by environmental factors. A more detailed knowledge of the
environmental factors and modifier genes involved in X-ALD, not only add to the
understanding of the molecular mechanism underlying different manifestations of X-ALD,
but might also open additional therapeutic opportunities.
CONCLUDING REMARKS
The adrenal insufficiency can be treated using steroid replacement therapy. For boys or
adolescents who show early evidence of inflammatory cerebral demyelination, allogenic
HSCT (78) can provide long-term benefit against the inflammatory demyelination.
Autologous HSC gene therapy (14) may likely become a therapeutic option for patients
without HLA-matched donors and adult patients with cerebral ALD, given the mortality risk
(35%) of allogeneic HSCT with full myeloablation. Attempts are taken for HSCT, as well as
for autologous HSC gene therapy, towards treatment of patients with early signs of
inflammation with increasing age. Unfortunately, for patients in whom inflammatory
demyelination has advanced too far for HSCT, all attempts of immunosuppressive or
immunomodulating therapies have not been successful. Lorenzo's oil is certainly not the
treatment of choice for the inflammatory form of X-ALD, as it has been shown that it cannot
prevent conversion to the inflammatory form even when administered before the onset.
Neither for male nor female X-ALD patients with AMN-related symptoms, satisfactory
treatment opportunities are available. Whether Lorenzo's oil delays or prevents symptoms in
some patients cannot be excluded but is not proven.
Concerning novel therapeutic approaches, antioxidative treatments can possibly be tested in
the near future and have a good rationale for being beneficial for male or female AMN
patients at any age. HDAC inhibitors like VPA, with the added benefit of reducing the
oxidative damage in X-ALD cells, provide more generalized neuroprotective effects that
have promising therapeutic potential also for X-ALD. The (possibly fortuitous) induction by
several HDAC inhibitors of the redundant gene ABCD2, adds to the rationale also for the
pharmacological induction of ABCD2, more directly targeting specific regulatory promoter
elements and critical cell types. The identification of compounds that are able to sufficiently
induce ABCD2 in microglia/macrophages, and the clarification whether or not these
compounds have to pass the blood–brain barrier are major research topics. If successful,
however, both CALD and AMN might be prevented by such treatment. Neurotrophic
factors, such as IGF-1 or NT-3, providing trophic support primarily for oligodendroglial
cells and axonal maintenance and, possibly indirectly, for neuronal integrity may be
considered for AMN. Continuous delivery of such therapeutic factors can be anticipated to
require either gene therapy using viral vectors or intrathecal implantation of encapsulated
cells genetically engineered to secrete them.
Thus in conclusion, there is hope that powerful new therapies will be developed in the near
future. These therapies are urgently needed for a large number of patients, for whom
currently no neuroprotective treatments are available. In particular, as some newborn
screening programs have already included X-ALD, more patients will be detected before
there is tissue damage and thus the future therapy can entirely focus on prevention of
damage.
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